Vigil

Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024

Retrieved on: 
Wednesday, March 6, 2024
Molecule, TREM2, Vigil, Pharmacology, Doctor of Philosophy, Microglia, Conference, Drug

WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today presented preclinical data on the profile of VG-3927 in an oral presentation at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases being held March 5 – March 9 in Lisbon Portugal.

Key Points: 
  • WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today presented preclinical data on the profile of VG-3927 in an oral presentation at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases being held March 5 – March 9 in Lisbon Portugal.
  • The presentation outlines preclinical data on the agonist pharmacology of VG-3927, its effect on AD-associated neuropathological endpoints, and its potential as a disease-modifying therapeutic for the treatment of AD.
  • “As the first and only small molecule TREM2 agonist to enter clinical development, we are thrilled to have an opportunity to further demonstrate the differentiated profile for VG-3927 and how it could represent a significant treatment advancement for those living with AD,” said David Gray, PhD, Chief Science Officer at Vigil.
  • “Having recently commenced dosing in our Phase 1 healthy volunteer clinical trial evaluating VG-3927, we look forward to further investigating this mechanism of action and its potential as a disease-modifying therapeutic.”
    Title: Characterization of the First Small Molecule TREM2 Agonist, VG-3927, for Clinical Development in Alzheimer’s Disease

Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on Three Key KRAS Mutations Identified in Drug Resistant Lung, Colon and Pancreatic Cancers

Retrieved on: 
Thursday, January 4, 2024
RNA interference, Vigil, Messenger, Cell, Small RNA, DNA, MD, Doctor of Philosophy, Cancer, Mutation, Gene silencing, Pancreatic cancer, Gene, Wang, STMN1, Rao, NSCLC, Vaccine

This approach may eliminate the need for multiple therapeutic compounds to address the different genes.

Key Points: 
  • This approach may eliminate the need for multiple therapeutic compounds to address the different genes.
  • Additionally, a precursor of GRAD1405 tested in a pancreatic cancer animal model showed improved benefit, suppression of tumor growth beyond 30 days and no evidence of resistance, over existing therapies.
  • GRAD1405 achieves the silencing of specific genes using Gradalis’ proprietary bi-shRNAi technology, which has consistently reduced targeted genes in clinical trials in multiple cancer indications.
  • Gradalis’ bi-shRNAi technology controls the DNA to protein pathway by an unprecedented two mechanisms: mRNA cleavage dependence and cleavage independence.

Gradalis Awarded $9.9 Million Grant From the Cancer Prevention and Research Institute of Texas

Retrieved on: 
Thursday, November 16, 2023
New product development, Research, Immune system, HRP, TILS, Cancer, Patient, PARP, VITAL, Ovarian cancer, MD, Trial of the century, Survival, Neoplasm, Research institute, Pharmaceutical industry, Vaccine, Vigil

These patients face an acutely high unmet medical need due to the removal of PARP inhibitor therapies in 2022.

Key Points: 
  • These patients face an acutely high unmet medical need due to the removal of PARP inhibitor therapies in 2022.
  • The study is designed as a pivotal trial to confirm the positive survival results seen in ovarian cancer patients with the HRP profile tumors in Gradalis’ earlier VITAL study in frontline maintenance therapy.
  • Clonal neoantigens are tumor initiating mutations, and research by others has shown that the targeting of clonal neoantigens predicts survival in cancer patients.
  • “Following the extensive review of several drug development opportunities, CPRIT was impressed with Gradalis' Vigil product activity and clinical benefit results.

Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE

Retrieved on: 
Thursday, November 16, 2023
Safety, Magnetic resonance imaging, Pathology, Disease, Clinical trial, TREM2, Patient, Medicine, FDA, Microglia, Caregiver, NHS England, Neurodegenerative disease, Osteopontin, Mayo Clinic, MRI, Biomarker, UCL Institute of Ophthalmology, IGNITE, HIV disease progression rates, AFL, Dietary supplement, Medical imaging, Communications satellite, Pharmaceutical industry, Vigil, CSF1R, Neurology, ALSP

"The positive interim results from our Phase 2 IGNITE trial represent the first clinical data reported from an interventional study in patients with ALSP and reaffirm our belief in the potential of iluzanebart as a novel treatment option.

Key Points: 
  • "The positive interim results from our Phase 2 IGNITE trial represent the first clinical data reported from an interventional study in patients with ALSP and reaffirm our belief in the potential of iluzanebart as a novel treatment option.
  • Key Highlights from Phase 2 IGNITE Interim Data:
    Favorable safety and tolerability profile, including no hematologic adverse events.
  • We believe the quality and consistency of the interim data further support the continuation of IGNITE without modification.
  • Interim Montreal Cognitive Assessment (MoCA) and Cortical Basal Ganglia Functional Scale data support use as clinical endpoints in ALSP at 12 months.

ManageEngine Enhances Its SIEM With Industry-First, Dual-Layered System for Precise and Accurate Threat Detection

Retrieved on: 
Wednesday, November 29, 2023
Data Management, Security, Technology, Software, Networks, Internet, MTTD, Zoho Corporation, Socs, AI, SOC, Organization, MTTR, Vigil, SIEM, Risk management

ManageEngine , the enterprise IT management division of Zoho Corporation, today unveiled the industry's first dual-layered threat detection system in its security information and event management (SIEM) solution, Log360.

Key Points: 
  • ManageEngine , the enterprise IT management division of Zoho Corporation, today unveiled the industry's first dual-layered threat detection system in its security information and event management (SIEM) solution, Log360.
  • The new feature, available in Log360's threat detection, investigation and response (TDIR) component, Vigil IQ, empowers security operations center (SOC) teams in organizations with improved accuracy and enhanced precision in threat detection.
  • To overcome these challenges, we recognize the imperative adoption of AI & ML for contextual event enrichment and rewiring threat detection logic," said Manikandan Thangaraj, vice president at ManageEngine.
  • Smart Alerts : Vigil IQ, the TDIR module of Log360, now combines the power of both accuracy and precision in threat detection.

LOBOS 1707 TEQUILA AND MEZCAL ANNOUNCES EXECUTIVE TEAM EXPANSION

Retrieved on: 
Monday, August 21, 2023
San Francisco World Spirits Competition, Culture, PX, FINNEAS, E-commerce, Southern Glazer's Wine and Spirits, Arnold Schwarzenegger, Vigil, Sport, LeBron James, Lobos 1707, Wine, Management, Mezcal

NEW YORK, Aug. 21, 2023 /PRNewswire/ -- Independent spirits producer Lobos 1707 Tequila and Mezcal announced today that Dia Simms has been appointed to serve as Executive Chairwoman of the Board and will transition from her current role as Chief Executive Officer. In addition, Carlos Vigil, experienced operator and veteran of the spirits industry, has joined the Lobos 1707 wolfpack as President and Chief Operating Officer. Simms helped build and lead Lobos 1707 since its inception in 2020 alongside Founder and Chief Creative Officer, Diego Osorio, with backing from founding investors Main Street Advisors and several of its clients, including sports and cultural icon LeBron James. Vigil joins Lobos 1707 after 15 years of executive leadership at the nation's biggest spirits distributor, Southern Glazers, where he led the company's commercial and digital transformation across sales, service & eCommerce.

Key Points: 
  • "Lobos 1707 has grown tremendously since our launch less than three years ago," said Simms, Executive Chairwoman of Lobos 1707.
  • "Lobos 1707 uniquely sits at the convergence of craft and culture," said Vigil, President and COO of Lobos 1707.
  • Lobos 1707 Tequila has earned numerous accolades within the spirits industry, including the Lobos 1707 Reposado Tequila winning Best in Class at the prestigious San Francisco World Spirits Competition.
  • Lobos 1707 Tequila and Mezcal was conceived not only to revive and share an ancestral recipe, but also to impact culture in a positive and vibrant way.

DispatchHealth Earns 2023 Great Place To Work Certification™

Retrieved on: 
Wednesday, July 19, 2023
Certification, Growth, Research, Patient, Great Places, Culture, Vigil, Nursing, Management

DENVER, July 19, 2023 /PRNewswire/ -- For the third year, DispatchHealth is proud to be Certified™ by Great Place To Work®, the global authority on workplace culture and employee experience.

Key Points: 
  • DENVER, July 19, 2023 /PRNewswire/ -- For the third year, DispatchHealth is proud to be Certified™ by Great Place To Work®, the global authority on workplace culture and employee experience.
  • This year, team members responded with the highest satisfaction yet: 78% said DispatchHealth is a great place to work, 21 points higher than the average U.S. company.
  • By successfully earning this recognition, it is evident that DispatchHealth stands out as one of the top companies to work for, providing a great workplace environment for its employees."
  • According to Great Place To Work research , job seekers are 4.5 times more likely to find a great boss at a Certified great workplace.

EWTN Announces Special Programming In Honor of Pope Emeritus Benedict

Retrieved on: 
Saturday, December 31, 2022
Catholic (term), Solemnity, Immaculate Conception, Theology, EWTN, Publishing, Basilica, Vigil, National Catholic Register, Soul, Angel, Concelebration, Woman, Nuncio, Multimedia, Auto Shanghai, Catholic News Agency, IHeartRadio, National shrine, Television, Radio, Interior design

IRONDALE, Ala., Dec. 31, 2022 /PRNewswire/ -- (EWTN) – In honor of Pope Emeritus Benedict, who passed away earlier today, EWTN will air the following special programming Saturday, Dec. 31.

Key Points: 
  • IRONDALE, Ala., Dec. 31, 2022 /PRNewswire/ -- (EWTN) – In honor of Pope Emeritus Benedict, who passed away earlier today, EWTN will air the following special programming Saturday, Dec. 31.
  • ET (encore): EWTN Live Special in honor of Pope Emeritus Benedict with Host Father Mitch Pacwa.
  • ET: Prayers for the Repose of the Soul of Pope Emeritus Benedict XVI (30 min.)
  • EWTN's website now includes a special tribute page to Pope Benedict which outlines his many accomplishments.

Bionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive Officer

Retrieved on: 
Thursday, December 15, 2022
Biogen, Corporations Act 2001, Psychiatry, Social anxiety disorder, Employment, Michele Cavion, CNS, ASX, Extraordinary general meeting, School, Public sector, Faculty, EVP, Central nervous system disease, Central nervous system, Vigil, Doctor of Philosophy, Neurology, BNO, Pfizer, SVP, EGM, MD, Neurodegeneration, Corporation, BNC210, Non-executive director, Hotel des Indes (The Hague), Allergan, Appendix (anatomy), Post-traumatic stress disorder, Therapy, FOR, University, Development, Patient, Pharmaceutical industry, Security (finance), Bionomics, Appendix

as President and Chief Executive Officer (CEO), effective 5 January 2023.

Key Points: 
  • as President and Chief Executive Officer (CEO), effective 5 January 2023.
  • Spyros is an experienced biopharmaceutical executive, a recognized neuroscientist/neurologist, and change agent with a 25-year career focused on CNS disorders.
  • Prior to joining Vigil, he served as Chief Development Officer, and SVP, Head of Development at Acadia Pharmaceuticals Inc., CEO at SwanBio Therapeutics, and EVP of Research & Development and Chief Medical Officer at Cavion.
  • The additional options are part of the compensation of Dr. De Souza for his period as Executive Chair of Bionomics.

DEKRA OPENS VEHICLE-GRID INNOVATION LABORATORY IN PARTNERSHIP WITH CALIFORNIA ENERGY COMMISSION

Retrieved on: 
Tuesday, December 6, 2022
Laboratory, DEKRA, Certification, FCC, Vigil, Jarin, Transport, California Energy Commission, Head, Plant, AMERICA, Joint Innovation Lab, Partnership, EV, Telekom Innovation Laboratories, Kerala Infrastructure Investment Fund Board, Part, Multimedia, Safety, OCPP, EVSE, Renewable energy, Concord

Created in partnership with the California Energy Commission, ViGIL seeks to transform the transportation sector by improving the interoperability of electric vehicles and charging infrastructure.

Key Points: 
  • Created in partnership with the California Energy Commission, ViGIL seeks to transform the transportation sector by improving the interoperability of electric vehicles and charging infrastructure.
  • "Interoperability is key to ensuring that electric vehicle drivers can easily charge their cars at any charging station," said Patty Monahan, Transportation Commissioner at the California Energy Commission.
  • The California Energy Commission is leading the state to a 100 percent clean energy future.
  • It has seven core responsibilities (bit.ly/3RGmpAY): developing renewable energy, transforming transportation, increasing energy efficiency, investing in energy innovation, advancing state energy policy, certifying thermal power plants, and preparing for energy emergencies.